NCT03484884Active, not recruiting
A Study of Optical Imaging With Light From Radiotracers in Cancer Patients
A Feasibility Study of Non-Invasive Cerenkov Luminescence Imaging in Patients With Cancer
Source: ClinicalTrials.gov · Last updated 28 Apr 2026
Brief summary (registry, in English)
The purpose of this study is to test Cerenkov luminescence imaging, which is a different way to take pictures of thyroid cancer and/or any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 102 (actual)
- First submitted
- 20 Mar 2018
- Start date
- 20 Mar 2018
- Primary completion date
- Mar 2027
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Thyroid cancer
- NCT number
- NCT03484884
What you commit to
- Study type: Observational
- Participants enrolled: 102
- From 20 Mar 2018 to the primary completion date, Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients imaged for Cerenkov luminescence are going to be required to be in a darkened enclosure for at least 10 minutes and sit still during image acquisition. Any conditions that would prevent this will exclude the patients. This includes patients who unable to sit in a dark environment, have claustrophobic, inability to sit still for a few minutes
Other
- Any other past medical, physiological or demographic concerns. This includes any patients with skin blemishes that are present at the dermis over the tumor, as these are of particular interest for use of this technique. This also includes open wounds on the area of interest.
Who the study is looking for
- Participant is 18 years of age or old
- Participant must meet one of the following:
- Patients with thyroid cancer scheduled for thyroid ablation therapy with 131I
- Patients with any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region who are scheduled to receive a clinical FDG PET/CT scan
- Patients with metastatic prostate cancer who are schedule for Xofigo therapy with 223Ra
- Patients scheduled to receive a standard of care 66Ga-DOTA-TATE or \[18f\]-PARPi PET scan in the Nuclear Medicine Clinic
- Patient undergoing Lu-DOTA TATE treatment in the Nuclear Medicine Clinic
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.